<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2FFE1135-E986-4E38-A807-F667FFD83D06"><gtr:id>2FFE1135-E986-4E38-A807-F667FFD83D06</gtr:id><gtr:firstName>Helene</gtr:firstName><gtr:surname>Plun-Favreau</gtr:surname><gtr:orcidId>0000-0002-1401-9656</gtr:orcidId><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700183"><gtr:id>DCAB9C41-A58F-4F57-AD74-5D501A1758DE</gtr:id><gtr:title>Identification of new components in Parkinson's Disease signalling pathways</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0700183</gtr:grantReference><gtr:abstractText>Our knowledge of the molecular events leading to Parkinson?s disease (PD) is being greatly enhanced by the study of familial forms of the disease. Professor Wood?s laboratory has identified a gene (PINK1) which when mutated causes nerve cell death and ultimately PD. Moreover, point mutations in a second gene called HtrA2 have also recently been identified as a susceptibility factor for PD. One of the first questions which arise is; do these two molecules interact either together or in the same pathway or process to produce PD? We have very recently established that they not only interact in the same pathway but that PINK1 regulates the activity of HtrA2. However much more work needs to be done to understand these processes more fully. This application focuses on this pathway and uses a range of molecular biological and cellular techniques to identify other proteins involved in this process. We plan to assess how these proteins talk to each other and how important this crosstalk is in the development of the disease. To this end we have already developed the core resources of appropriate cell models and have identified human brain tissue carrying abnormalities in the PINK1 gene. Moreover, we will have access to mice and flies in which HtrA2 and PINK1 genes have been disrupted.

If we can indeed discover more of the pathway to cell dysfunction and death, then this in turn provides more options for therapeutic intervention.</gtr:abstractText><gtr:technicalSummary>The identification of genes responsible for mendelian forms of Parkinson?s disease (PD) has transformed our understanding of the molecular pathogenesis of nigral neurodegeneration. Whether these mendelian genes interact, and which signalling pathways are disrupted in PD remain unknown. The aim of this project is to characterise a molecular pathway that appears to be of major significance in PD. 

Mutations in the PINK1 gene are known to cause PD. PINK1 is a mitochondrial putative kinase which exerts a neuroprotective function. Mutations in HtrA2, a mitochondrial serine protease, have also been identified in patients with PD. Targeted deletion of HtrA2 in mice causes mitochondrial dysfunction leading to a neurodegenerative disorder with parkinsonian features. We have shown for the first time that HtrA2 interacts with PINK1 and both are components of the same stress-sensing pathway. Phosphorylation of HtrA2 takes place in a PINK1 dependent manner and HtrA2 phosphorylation is decreased in brains of PD patients carrying PINK1 mutations. We hypothesise that PINK1-dependent phosphorylation of HtrA2 may modulate its proteolytic activity, thereby contributing to increased resistance of neurons to mitochondrial stress.
 
A range of techniques will be employed in a variety of in vitro and in vivo models to dissect the HtrA2/PINK1 pathway. The project has four major objectives:
 - To determine the functional effect of specific PD-associated PINK1 mutations on HtrA2 phosphorylation. This will be studied using human post-mortem brain with PINK1 mutations, and PINK1 knockout mouse cells re-expressing mutant forms of PINK1. 
 - To identify other members of the HtrA2/PINK1 signalling pathway. Expression of a tandem affinity purification (TAP)-tagged version of HtrA2 in HEK293 cells has enabled the co-purification of PINK1 as well as other putative interacting partners. A combination of phospho-proteomic approaches and biological assays using RNAi technology will be used to aluate the relevance of other interactors within the same pathway.
 - To elucidate the functional interaction between the HtrA2/PINK1 pathway and other mendelian genes, in particular parkin. The HtrA2, PINK1 and parkin knockout flies and mice will be used to explore the proposed functional link between PINK1 and parkin. 
 - To investigate whether mutations in other members of this pathway are responsible for familial PD. The IoN has over 100 familial PD cases with as yet unidentified gene defects. Functional data emerging from these studies will be used in a candidate gene discovery approach to identify new mendelian forms of PD. 

Characterisation of this signalling pathway will have a major impact on our understanding of the pathogenesis of sporadic PD, and will ultimately drive target discovery for developing new therapies in PD.</gtr:technicalSummary><gtr:fund><gtr:end>2013-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>994883</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>PDUK: Understanding Parkinson's disease, lessons from biology</gtr:description><gtr:id>F6E750B2-504B-4B26-AAD1-D58FFB9A7D75</gtr:id><gtr:impact>PMID: 22739987
PMID: 23498975 
PMID: 23933751
PMID: 26893374
PMID: 27689878</gtr:impact><gtr:outcomeId>Q1sLfadvZkn-1</gtr:outcomeId><gtr:partnerContribution>Experimental workExperimental work</gtr:partnerContribution><gtr:piContribution>Investigating the functions of the new Parkinson's disease genes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Protein Phosphorylation and Ubiquitylation Unit</gtr:department><gtr:description>PDUK: Understanding Parkinson's disease, lessons from biology</gtr:description><gtr:id>63A7FCD1-BD4B-4F39-9D82-765E583DACB0</gtr:id><gtr:impact>PMID: 22739987
PMID: 23498975 
PMID: 23933751
PMID: 26893374
PMID: 27689878</gtr:impact><gtr:outcomeId>Q1sLfadvZkn-2</gtr:outcomeId><gtr:partnerContribution>Experimental workExperimental work</gtr:partnerContribution><gtr:piContribution>Investigating the functions of the new Parkinson's disease genes</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Investigating signaling pathway dysfunction linked to LRRK2</gtr:description><gtr:id>B726A228-0050-4E71-8811-B3FA0092D7E8</gtr:id><gtr:impact>PMID: 27731364
PMID: 24211199
PMID: 23916833</gtr:impact><gtr:outcomeId>mgw7XsquMc3-1</gtr:outcomeId><gtr:partnerContribution>Contribution to experiments</gtr:partnerContribution><gtr:piContribution>Design of the experiments</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy</gtr:description><gtr:id>19679E50-E5AD-488D-90B2-BF3FA4F63DB4</gtr:id><gtr:impact>PMID: 23933751
PMID: 27689878</gtr:impact><gtr:outcomeId>545ba86b87a2f1.82013932-1</gtr:outcomeId><gtr:partnerContribution>In vivo work in flies with Sheffield university (Alex Whitworth)

Biochemistry with Cambridge university (Heike Laman)</gtr:partnerContribution><gtr:piContribution>Compelling evidence indicates that two autosomal recessive Parkinson's disease genes, PINK1 (PARK6) and Parkin (PARK2), cooperate to mediate the autophagic clearance of damaged mitochondria (mitophagy). Mutations in the F-box domain-containing protein Fbxo7 (encoded by PARK15) also cause early-onset autosomal recessive Parkinson's disease, by an unknown mechanism. Here we show that Fbxo7 participates in mitochondrial maintenance through direct interaction with PINK1 and Parkin and acts in Parkin-mediated mitophagy. Cells with reduced Fbxo7 expression showed deficiencies in translocation of Parkin to mitochondria, ubiquitination of mitofusin 1 and mitophagy. In Drosophila, ectopic overexpression of Fbxo7 rescued loss of Parkin, supporting a functional relationship between the two proteins. Parkinson's disease-causing mutations in Fbxo7 interfered with this process, emphasizing the importance of mitochondrial dysfunction in Parkinson's disease pathogenesis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Genetics</gtr:department><gtr:description>The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy</gtr:description><gtr:id>B00763FF-A2B6-48AE-966E-626DBA8319B5</gtr:id><gtr:impact>PMID: 23933751
PMID: 27689878</gtr:impact><gtr:outcomeId>545ba86b87a2f1.82013932-2</gtr:outcomeId><gtr:partnerContribution>In vivo work in flies with Sheffield university (Alex Whitworth)

Biochemistry with Cambridge university (Heike Laman)</gtr:partnerContribution><gtr:piContribution>Compelling evidence indicates that two autosomal recessive Parkinson's disease genes, PINK1 (PARK6) and Parkin (PARK2), cooperate to mediate the autophagic clearance of damaged mitochondria (mitophagy). Mutations in the F-box domain-containing protein Fbxo7 (encoded by PARK15) also cause early-onset autosomal recessive Parkinson's disease, by an unknown mechanism. Here we show that Fbxo7 participates in mitochondrial maintenance through direct interaction with PINK1 and Parkin and acts in Parkin-mediated mitophagy. Cells with reduced Fbxo7 expression showed deficiencies in translocation of Parkin to mitochondria, ubiquitination of mitofusin 1 and mitophagy. In Drosophila, ectopic overexpression of Fbxo7 rescued loss of Parkin, supporting a functional relationship between the two proteins. Parkinson's disease-causing mutations in Fbxo7 interfered with this process, emphasizing the importance of mitochondrial dysfunction in Parkinson's disease pathogenesis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Developmental and Biomedical Genetics</gtr:department><gtr:description>PDUK: Understanding Parkinson's disease, lessons from biology</gtr:description><gtr:id>E7BBE2DE-5ADD-43F8-9558-2171B982AC0E</gtr:id><gtr:impact>PMID: 22739987
PMID: 23498975 
PMID: 23933751
PMID: 26893374
PMID: 27689878</gtr:impact><gtr:outcomeId>Q1sLfadvZkn-3</gtr:outcomeId><gtr:partnerContribution>Experimental workExperimental work</gtr:partnerContribution><gtr:piContribution>Investigating the functions of the new Parkinson's disease genes</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>65600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL Central Research Committee (Phosphorylation of HtrA2 by CDK5- Implications in Parkinson's Disease.)</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>4B851763-9265-4F04-899A-8C8F7F1AB034</gtr:id><gtr:outcomeId>gWbMxqXmnNP0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9058020</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investigating the functioinal significance between PINK1 and mortalin - two genes implicated in Parkinson's disease</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:id>84155050-133C-4DCD-BF00-EBFDD87DD4CF</gtr:id><gtr:outcomeId>JJNyXxbGmyw0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>390000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Understanding LRRK2 biology grant: Investigating signaling dysfunction linked to LRRK2</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>9F7E09CB-DA04-4E2A-9D6F-BE6D4499A78C</gtr:id><gtr:outcomeId>L55FbKa1CFn0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Understanding Parkinson's disease, lessons from biology/Wellcome/MRC neurodegenerative disease strategic awards</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>B8F00442-06BD-49E0-A3F4-0FB5FA10167C</gtr:id><gtr:outcomeId>hSfZMLfj82n0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>91389</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Identification of new components in HtrA2/PINK1 signallimg pathways/MRC/BRT studentship for Victoria Burchell</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0681081F-AEFA-4DD7-8654-0DE05620ECFB</gtr:id><gtr:outcomeId>dc7mcnBfjSp0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>PINK1 and parkin knockdown SH-SY5Y cells
SH-SY5Y cells over-expressing PINK1 and parkin Parkinson's disease mutants</gtr:description><gtr:id>C2EAEB3C-622D-4E7F-8679-A520F869108B</gtr:id><gtr:impact>see publications</gtr:impact><gtr:outcomeId>noMLx1VrUdm</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PINK1, parkin cell lines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Rabbit polyclonal antibody
Application: Western blot</gtr:description><gtr:id>8D478462-22C5-41CE-92C7-6A2B7DE8D32A</gtr:id><gtr:impact>Fitzgerald JC, Camprubi MD, Dunn L, Wu HC, Ip NY, Kruger R, Martins LM, Wood NW, Plun-Favreau H.
Cell Death Differ. 2011 Jun 24.</gtr:impact><gtr:outcomeId>gWrWAJgkRcB</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Phospho-Ser400 HtrA2 antibody</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Homozygous Parkin fibroblasts</gtr:description><gtr:id>A2521871-C0A0-426B-B552-0002CB75C31E</gtr:id><gtr:impact>work in progress</gtr:impact><gtr:outcomeId>bLKwaU144NG</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Human patient fibroblasts</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D6F5F128-83A0-4446-9468-6DC8DF91C320</gtr:id><gtr:title>Mitophagy and Parkinson's disease: the PINK1-parkin link.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/948b5c491080c769d4906f5e34a78056"><gtr:id>948b5c491080c769d4906f5e34a78056</gtr:id><gtr:otherNames>Deas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>Rvuw4oc6kGB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED188BAD-AE16-4741-949B-4983ACEDA966</gtr:id><gtr:title>Parkinson's disease and cancer: two wars, one front.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81b016b620411b3da51cfd468ebe3c2a"><gtr:id>81b016b620411b3da51cfd468ebe3c2a</gtr:id><gtr:otherNames>Devine MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn><gtr:outcomeId>UM2SmnUV6A4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>667FFBC5-D2FA-4A56-840D-61AD61B4D976</gtr:id><gtr:title>What have PINK1 and HtrA2 genes told us about the role of mitochondria in Parkinson's disease?</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1a768ac0348b89871dc88cb7217499f"><gtr:id>d1a768ac0348b89871dc88cb7217499f</gtr:id><gtr:otherNames>Plun-Favreau H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>Y67zxSkyuyf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F02CB25-AB9D-4795-B29F-3F43A43F6B73</gtr:id><gtr:title>Phosphorylation of HtrA2 by cyclin-dependent kinase-5 is important for mitochondrial function.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1825a11096392cdb4a65efacbb12473"><gtr:id>b1825a11096392cdb4a65efacbb12473</gtr:id><gtr:otherNames>Fitzgerald JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>rcq74j4kDCq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F7891D7-2F10-4CFC-9C90-8FE917DBCC6A</gtr:id><gtr:title>Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific transcriptional stress response.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3edc2144895ea1217098953b44b7e7f"><gtr:id>e3edc2144895ea1217098953b44b7e7f</gtr:id><gtr:otherNames>Moisoi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>BFf5QnaEmbQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>175818B8-5547-4E4E-8524-A0376415684A</gtr:id><gtr:title>Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fedc4404d626048147a389c1d14ecc32"><gtr:id>fedc4404d626048147a389c1d14ecc32</gtr:id><gtr:otherNames>Bartolome F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>pm_14807_27_23498975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E48D753-9026-4374-9362-C5573FF63780</gtr:id><gtr:title>Intracellular pH Modulates Autophagy and Mitophagy.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6267bf86ce44279c129d55f2a5c689bd"><gtr:id>6267bf86ce44279c129d55f2a5c689bd</gtr:id><gtr:otherNames>Berezhnov AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>56d9a4d32e4625.11914356</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>129D5F62-0138-4919-9888-DCC62F1FC425</gtr:id><gtr:title>Lysine 27 ubiquitination of the mitochondrial transport protein Miro is dependent on serine 65 of the Parkin ubiquitin ligase.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af2d5f2e04b285bdff9667c446ba5cae"><gtr:id>af2d5f2e04b285bdff9667c446ba5cae</gtr:id><gtr:otherNames>Birsa N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>545ba514a93c87.62086228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38248DB9-25F7-41BA-A790-A8871DA8ECF8</gtr:id><gtr:title>Drosophila HtrA2 is dispensable for apoptosis but acts downstream of PINK1 independently from Parkin.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4af53352591f43e62822b8dbd2da2227"><gtr:id>4af53352591f43e62822b8dbd2da2227</gtr:id><gtr:otherNames>Tain LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>pm_14807_17_19282869</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BF7081B-DBD4-46E2-A3FD-D00A8E15E097</gtr:id><gtr:title>Mutations and mechanism: how PINK1 may contribute to risk of sporadic Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe26393ce1a826c37d2c03b54270978"><gtr:id>7fe26393ce1a826c37d2c03b54270978</gtr:id><gtr:otherNames>Gandhi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>58bec6f4ea0427.08892531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EFDE0B3-0476-4DEB-8C35-66F108B5BC27</gtr:id><gtr:title>Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.</gtr:title><gtr:parentPublicationTitle>Expert opinion on therapeutic targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e905395803df499a5bf946eb9e5153e0"><gtr:id>e905395803df499a5bf946eb9e5153e0</gtr:id><gtr:otherNames>Burchell VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1472-8222</gtr:issn><gtr:outcomeId>DFMCCNXDAsW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1696E6F-85E3-477D-9221-D8EEF8B64C26</gtr:id><gtr:title>The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e905395803df499a5bf946eb9e5153e0"><gtr:id>e905395803df499a5bf946eb9e5153e0</gtr:id><gtr:otherNames>Burchell VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>doi_55f984984563325c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>784FF263-05AB-401A-A2D7-A2036D6ED625</gtr:id><gtr:title>PINK1 cleavage at position A103 by the mitochondrial protease PARL.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/948b5c491080c769d4906f5e34a78056"><gtr:id>948b5c491080c769d4906f5e34a78056</gtr:id><gtr:otherNames>Deas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>S1RcoZd95WY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D83D4E9B-7C86-4C09-A679-B469A78877F5</gtr:id><gtr:title>Deficiency of Parkinson's disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9278766eee834d07339349f98cb5d9fc"><gtr:id>9278766eee834d07339349f98cb5d9fc</gtr:id><gtr:otherNames>Delgado-Camprubi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>58481ffbe41f28.16896996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D4D9D2E-E989-4D13-91C8-4F7FD8C307F3</gtr:id><gtr:title>Cell metabolism affects selective vulnerability in PINK1-associated Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/521f8366c59ab87c062c9c49a518c4b8"><gtr:id>521f8366c59ab87c062c9c49a518c4b8</gtr:id><gtr:otherNames>Yao Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>pm_14807_27_22223879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>643ED18E-E025-4DF8-BF22-23A566AF16ED</gtr:id><gtr:title>PINK1 in mitochondrial function.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1a768ac0348b89871dc88cb7217499f"><gtr:id>d1a768ac0348b89871dc88cb7217499f</gtr:id><gtr:otherNames>Plun-Favreau H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>qjjP4VsHN2L</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CC8CBC3-2C38-4E89-B137-DC2C9F4DB693</gtr:id><gtr:title>Cancer and neurodegeneration: between the devil and the deep blue sea.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1a768ac0348b89871dc88cb7217499f"><gtr:id>d1a768ac0348b89871dc88cb7217499f</gtr:id><gtr:otherNames>Plun-Favreau H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>iBX7cTtha3x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CD28292-B90D-4477-AA61-2B7ED9909C06</gtr:id><gtr:title>Emerging pathways in genetic Parkinson's disease: autosomal-recessive genes in Parkinson's disease--a common pathway?</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1825a11096392cdb4a65efacbb12473"><gtr:id>b1825a11096392cdb4a65efacbb12473</gtr:id><gtr:otherNames>Fitzgerald JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>YrWk9vAb9WU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98DE25BE-4BA5-4E5E-B9C2-F569135894AB</gtr:id><gtr:title>Targeting mitochondrial dysfunction in neurodegenerative disease: Part II.</gtr:title><gtr:parentPublicationTitle>Expert opinion on therapeutic targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e905395803df499a5bf946eb9e5153e0"><gtr:id>e905395803df499a5bf946eb9e5153e0</gtr:id><gtr:otherNames>Burchell VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1472-8222</gtr:issn><gtr:outcomeId>WiFLEnzP47x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C452F274-C56C-4A9A-A166-F4FDB35871B7</gtr:id><gtr:title>mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3986e9193670c92aaeae6a29e24b678e"><gtr:id>3986e9193670c92aaeae6a29e24b678e</gtr:id><gtr:otherNames>Manzoni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58481ffbb9b587.87600835</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26C78307-E5BE-4EC3-876B-864FEF5C21C8</gtr:id><gtr:title>PINK1 function in health and disease.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/948b5c491080c769d4906f5e34a78056"><gtr:id>948b5c491080c769d4906f5e34a78056</gtr:id><gtr:otherNames>Deas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>HcupkquPj27</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C3A0C4B-7591-4256-98FB-2F6A88D18B22</gtr:id><gtr:title>HtrA2 deficiency causes mitochondrial uncoupling through the F1F0-ATP synthase and consequent ATP depletion.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1a768ac0348b89871dc88cb7217499f"><gtr:id>d1a768ac0348b89871dc88cb7217499f</gtr:id><gtr:otherNames>Plun-Favreau H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>pm_14807_27_22739987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F1A4196-858D-4B27-9786-7E791FFC9A80</gtr:id><gtr:title>PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe26393ce1a826c37d2c03b54270978"><gtr:id>7fe26393ce1a826c37d2c03b54270978</gtr:id><gtr:otherNames>Gandhi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>MzuUqNpj3p6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE6A046F-4F6F-48B7-9363-4B438277751F</gtr:id><gtr:title>The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1a768ac0348b89871dc88cb7217499f"><gtr:id>d1a768ac0348b89871dc88cb7217499f</gtr:id><gtr:otherNames>Plun-Favreau H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>KP9oq4VfYiM</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700183</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>